Open Access Email this article to a friend

Maraviroc, a chemokine receptor-5 antagonist, fails to demonstrate efficacy in the treatment of patients with rheumatoid arthritis in a randomized, double-blind placebo-controlled trial

Dona L Fleishaker*, Juan A Garcia Meijide, Andriy Petrov, Michael David Kohen, Xin Wang, Sujatha Menon, Thomas C Stock, Charles A Mebus, James M Goodrich, Howard B Mayer and Bernhardt G Zeiher

Arthritis Research & Therapy 2012, 14:R11  doi:10.1186/ar3685

See related editorial by Takeuchi and Kameda,

Fields marked * are required

Multiple email addresses should be separated with commas or semicolons.
How can I ensure that I receive Arthritis Research & Therapy's emails?